Advances in the management of Hodgkin's and non-Hodgkin's lymphoma

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 259-263

  Davis, Thomas A ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

ANGIONEUROTIC EDEMA; ASTHENIA; BLOOD TOXICITY; BRONCHOSPASM; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CHILL; DRUG MEGADOSE; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HYPOTENSION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032412634     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00005     Document Type: Review

References (18)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation •• of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997, 89:3909-918. This article supports the pathologic reproducibility and prognostic capacity of the Revised European-American Lymphoma classification system for NHL. Clinical correlation with immunohistochemistry and overall survival are discussed.
2. Carbone A: HHV-8-positive body-cavity-based lymphoma: a novel •• lymphoma entity. Br J Haematol 1997, 97:515-522. Identification of the association of the infectious human herpesvirus-8 with a new type of lymphoma.
3. Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, • Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, Berenson JR: Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997, 90:4278-4782. Documents the localization of human herpesvirus-8 in the marrow of patients with multiple myeloma.
4. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR: Kaposi's sarcomaassociated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1851-1854.
5. Sarid R, Sato T, Bohenzky R, Russo J, Chang Y: Kaposi's sarcoma-associ• ated herpesvirus encodes a functional Bcl-2 homologue. Nat Med 1997, 3:293-298. Identifies the presence of an oncogene associated with lymphoma within the genome of human herpesvirus-8.
6. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
7. Maloney DG, Liles TM, Czerwinski DK, Waldichuck C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457-2466.
8. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: results of a phase I multipledose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274. Preliminary clinical data showing the safety and efficacy of rituximab, a new clinical agent for the therapy of B-cell, low-grade, and follicular NHL.
9. Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J, • Janakiraman N, Foon K, Liles T, Dallaire B, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195. Preliminary clinical data showing the safety and efficacy of rituximab, a new clinical agent for the therapy of B-cell, low-grade, and follicular NHL. Initially defines an excellent toxicity profile and a response rate of approximately 50%
10. McLaughlin P, Cabanillas F, Grillo-Lopez A, Link B, Levy R, Czuczman M, •• Heyman M, Williams M, Jain V, Bence-Bruckler I, Ho A, Lister J, Rosenberg J, Dallaire B, Shen D: IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low grade or follicular lymphoma [abstract]. Blood 1996, 88:349.
11. Davis T, Levy R, White C, Maloney D, Link B, Velasquez W, Varns C, •• Gardner C, Grillo-Lopez A: Retreatments with rituximab have significant efficacy, do not cause HAMA, are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma [abstract]. Blood 1997, 90:2269. Confirms the safety and efficacy (response rate of 44% in prior responders) of rituximab for repeated use.
12. Webb A, Cunningham D, Cotter F, Clarke P, di Stefano F, Ross P, Corbo •• M, and Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet 1997, 349:1137-1141. Preliminary data on the safety and efficacy of antisense therapy targeting the BCL2 gene. Clinical responses are identified.
13. Nalesnik M, Rao A, Furukawa H, Pham S, Zeevi A, Fung J, Klein G, Gritsch •• A, Elder E, Whiteside T, Starzl T: Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997, 63:1200-1205. Presents a feasible and minimally toxic cellular therapy for EBV-positive PTLD. Dramatic clinical results are seen in EBV-positive patients in this article.
14. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, •• Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997, 89:3129-3135. Data showing improved outcome in patients who have undergone vaccination with the tumor-specific idiotype protein and have mounted a measurable specific anti-idiotype immune response.
15. Bierman P, Vose J, Anderson J, Bishop M, Kessinger A, Armitage J: High• dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:445-450. An historical evaluation supporting prolonged remission but not cure in patients with low-grade lymphoma who have undergone autologous bone marrow transplantation.
16. Glick J, Young M, Harrington D, Schilsky R, Beck T, Neiman R, Fisher R, Peterson B, Oken M: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8 year results of the intergroup trial. J Clin Oncol 1998, 16:19-26.
17. Connors J, Klimo P, Adams G, Burns B, Cooper I, Meyer R, O'Reilly S, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S. Verma S, Yoshida S, Zee B: Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997, 15:1638-1645.
18. Weiner M, Leventhal B, Brecher M, Marcus R, Cantor A, Gieser P, Ternberg J, Behm F, Wharam M, Chauvenet A: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997, 15:2769-2779.